Life After the IPO: What Does Apellis Have Planned After Raising $170m from Public Investors?

Apellis’ Francois Debriefs After JP Morgan Debut

Episode 169

Cedric Francois, president and CEO, discusses his debut performance at JP Morgan in which he laid out the company’s plans for a Phase III trial of APL-2, the promising treatment for geographic atrophy. Francois shared the details of the trial, talked about going public, and shared one of the least recognized – but most important – challenges facing biopharma companies.

Do You Have

A STORY TO TELL?

If you’d like to be considered as a guest on a future episode of the OIS podcast, please complete the application today.

Meet Our Host

TOM SALEMI

Tom-Salemi

Joining the company in 2014, to create and manage a new line of podcasts, publications and other editorial products.

Subscribe

ON iTUNES

Don't miss an episode. Join the conversation by visiting our podcast channel on iTunes today and subscribe. Is fast and is free!

STAY UP TO DATE WITH OIS

Get the Latest News, Podcasts and Videos.